MA34490B1 - Procede de production d'un compose intermediaire pour la synthese d'un medicament - Google Patents

Procede de production d'un compose intermediaire pour la synthese d'un medicament

Info

Publication number
MA34490B1
MA34490B1 MA35699A MA35699A MA34490B1 MA 34490 B1 MA34490 B1 MA 34490B1 MA 35699 A MA35699 A MA 35699A MA 35699 A MA35699 A MA 35699A MA 34490 B1 MA34490 B1 MA 34490B1
Authority
MA
Morocco
Prior art keywords
synthesis
producing
intermediate compound
medicinal product
compound
Prior art date
Application number
MA35699A
Other languages
English (en)
Inventor
Bong Chan Kim
Kyu Young Kim
Hee Bong Lee
Ji Eun An
Kyu Woong Lee
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of MA34490B1 publication Critical patent/MA34490B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Cette invention concerne un nouveau procédé de préparation d'un composé de formule (2) à titre d'intermédiaire, qui peut être efficacement utilisé pour préparer un composé de formule (1) manifestant une bonne activité inhibitrice contre l'enzyme dipeptidyl-peptidase IV.
MA35699A 2010-09-03 2011-08-25 Procede de production d'un compose intermediaire pour la synthese d'un medicament MA34490B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100086619 2010-09-03
PCT/KR2011/006260 WO2012030106A2 (fr) 2010-09-03 2011-08-25 Procédé de production d'un composé intermédiaire pour la synthèse d'un médicament

Publications (1)

Publication Number Publication Date
MA34490B1 true MA34490B1 (fr) 2013-08-01

Family

ID=45023417

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35699A MA34490B1 (fr) 2010-09-03 2011-08-25 Procede de production d'un compose intermediaire pour la synthese d'un medicament

Country Status (32)

Country Link
US (1) US8741927B2 (fr)
EP (1) EP2611776B1 (fr)
JP (1) JP5705985B2 (fr)
KR (1) KR101378984B1 (fr)
CN (1) CN103080088B (fr)
AP (1) AP3270A (fr)
AR (1) AR082881A1 (fr)
AU (1) AU2011296767B2 (fr)
BR (1) BR112013004988B1 (fr)
CA (1) CA2810393C (fr)
CL (1) CL2013000589A1 (fr)
CO (1) CO6700826A2 (fr)
DK (1) DK2611776T3 (fr)
EA (1) EA022500B1 (fr)
EC (1) ECSP13012471A (fr)
ES (1) ES2607089T3 (fr)
HK (1) HK1184787A1 (fr)
HU (1) HUE032484T2 (fr)
IL (1) IL224954B (fr)
MA (1) MA34490B1 (fr)
MX (1) MX2013002277A (fr)
MY (1) MY157423A (fr)
NZ (1) NZ607694A (fr)
PE (1) PE20131128A1 (fr)
PL (1) PL2611776T3 (fr)
PT (1) PT2611776T (fr)
SG (1) SG188329A1 (fr)
SI (1) SI2611776T1 (fr)
TW (1) TWI438188B (fr)
UA (1) UA107721C2 (fr)
UY (1) UY33589A (fr)
WO (1) WO2012030106A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995612A1 (fr) * 2014-09-12 2016-03-16 Université de Strasbourg Nouveaux acides aminés non naturels, leur procédé de préparation et leurs utilisations
KR102068754B1 (ko) * 2017-04-20 2020-01-21 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
BR112020006063B1 (pt) * 2017-09-28 2024-01-16 Lg Chem, Ltd Método para a preparação de um composto intermediário para sintetizar medicamentos antidiabéticos
MX2020003543A (es) * 2017-09-28 2020-07-29 Lg Chemical Ltd Metodo de produccion de un compuesto intermediario para sintetizar un medicamento.
WO2019098551A1 (fr) * 2017-11-16 2019-05-23 주식회사 엘지화학 Procédé de préparation de composé intermédiaire d'une synthèse pharmaceutique
BR112020009568A2 (pt) * 2017-11-16 2021-03-09 Lg Chem, Ltd. Método de produção de composto intermediário para síntese de medicamento
CN113861061A (zh) * 2021-10-25 2021-12-31 成都市科隆化学品有限公司 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456768A (en) * 1980-10-08 1984-06-26 The University Of Chicago Chemical synthesis
US5556982A (en) * 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE3705272A1 (de) 1987-02-19 1988-09-01 Basf Ag Verfahren zur reduktion von mono- und dicarbonsaeuren
US5417023A (en) * 1993-12-27 1995-05-23 Mandish; Theodore O. Building panel apparatus and method
IL151018A0 (en) * 2000-03-17 2003-02-12 Bristol Myers Squibb Pharma Co Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
CN101522190A (zh) * 2006-08-09 2009-09-02 史密丝克莱恩比彻姆公司 作为孕酮受体调节剂的吡咯烷酮苯胺
KR20080071476A (ko) * 2007-01-30 2008-08-04 주식회사 엘지생명과학 신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
AU2008341352B2 (en) * 2007-12-21 2013-08-01 Lg Chem, Ltd. Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent

Also Published As

Publication number Publication date
CA2810393A1 (fr) 2012-03-08
PT2611776T (pt) 2016-12-20
UY33589A (es) 2011-12-01
JP5705985B2 (ja) 2015-04-22
BR112013004988A2 (pt) 2016-05-31
CO6700826A2 (es) 2013-06-28
AU2011296767B2 (en) 2015-04-23
JP2013543484A (ja) 2013-12-05
BR112013004988B1 (pt) 2020-07-28
AU2011296767A1 (en) 2013-03-14
ECSP13012471A (es) 2013-04-30
US8741927B2 (en) 2014-06-03
MY157423A (en) 2016-06-15
WO2012030106A2 (fr) 2012-03-08
EP2611776A2 (fr) 2013-07-10
CL2013000589A1 (es) 2013-07-12
UA107721C2 (ru) 2015-02-10
HUE032484T2 (en) 2017-09-28
AR082881A1 (es) 2013-01-16
ES2607089T3 (es) 2017-03-29
KR101378984B1 (ko) 2014-03-27
AP2013006763A0 (en) 2013-03-31
PE20131128A1 (es) 2013-10-18
EA201390336A1 (ru) 2013-07-30
IL224954B (en) 2018-11-29
NZ607694A (en) 2015-08-28
WO2012030106A3 (fr) 2012-05-18
PL2611776T3 (pl) 2017-06-30
HK1184787A1 (en) 2014-01-30
TW201213297A (en) 2012-04-01
CN103080088B (zh) 2014-09-24
KR20120060139A (ko) 2012-06-11
SG188329A1 (en) 2013-04-30
DK2611776T3 (en) 2017-01-09
AP3270A (en) 2015-05-31
MX2013002277A (es) 2013-05-22
CA2810393C (fr) 2016-04-12
SI2611776T1 (sl) 2017-03-31
US20130165659A1 (en) 2013-06-27
EP2611776B1 (fr) 2016-09-21
EP2611776A4 (fr) 2014-08-20
TWI438188B (zh) 2014-05-21
CN103080088A (zh) 2013-05-01
EA022500B1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
MA34490B1 (fr) Procede de production d'un compose intermediaire pour la synthese d'un medicament
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
DOP2012000225A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PH12015500211B1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
MX2014000536A (es) Compuestos de 4-piperidinilo para usarse como inhibidores de tanquirasa.
TN2013000362A1 (en) Benzodioxane inhibitors of leukotriene production
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
TN2014000112A1 (en) Ep1 receptor ligands
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MX2012008635A (es) Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos.
MX340370B (es) Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas.
MX337173B (es) Derivados de acido 3-heteroaroilamino-propionico y sus usos como productos farmeceuticos.
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
MA34880B1 (fr) Procede de synthese enzymatique de la (7s)-1-(3,4-dimethoxy bicyclo[4.2.0] octa-1,3,5-triene 7-yl) n-methyl methanamine, et application a la synthese de l'ivabradine et de ses sels
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
TN2013000075A1 (en) Production method of intermediate compound for synthesizing medicament
HK1136288A1 (fr)
WO2012085935A3 (fr) Composés utilisés comme inhibiteurs de la rénine
TN2013000052A1 (en) Oxadiazole inhibitors of leukotriene production
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production
MY152686A (en) Thienopyrimidinedione derivative as trpa1 modulators